Publications by authors named "Stefania Pirrotta"
Article Synopsis
- Understanding cancer involves exploring mechanisms, categorizing subtypes, predicting outcomes, and evaluating treatment effectiveness, with gene-expression signatures being vital tools over the last decade.
- Recent technological advancements like single-cell RNA sequencing have exposed the complexity of tumor cells, prompting the need for new computational tools to analyze this heterogeneity accurately.
- The R Bioconductor package "signifinder" helps streamline the use of cancer transcriptional signatures across various data types, enhancing the analysis of tumor features through case studies that illustrate its effectiveness in oncology research.
Epithelial ovarian cancer is a significant global health issue among women. Diagnosis and treatment pose challenges due to difficulties in predicting patient responses to therapy, primarily stemming from gaps in understanding tumor chemoresistance mechanisms. Recent advancements in transcriptomic technologies like single-cell RNA sequencing and spatial transcriptomics have greatly improved our understanding of ovarian cancer intratumor heterogeneity and tumor microenvironment composition.
View Article and Find Full Text PDFOver the last decade, many studies and some clinical trials have proposed gene expression signatures as a valuable tool for understanding cancer mechanisms, defining subtypes, monitoring patient prognosis, and therapy efficacy. However, technical and biological concerns about reproducibility have been raised. Technical reproducibility is a major concern: we currently lack a computational implementation of the proposed signatures, which would provide detailed signature definition and assure reproducibility, dissemination, and usability of the classifier.
View Article and Find Full Text PDFIntroduction: Patients with diabetes and coronary artery disease remain at high risk for adverse cardiovascular events after percutaneous coronary intervention. The efficacy and safety of the various drug-eluting stents (DES) in patients with diabetes is unclear.
Methods: Randomized controlled trials comparing first-generation DES [paclitaxel-eluting stents (PES) and sirolimus-eluting stents (SES)] with everolimus-eluting stents (EES) and zotarolimus-eluting stents (ZES) in diabetic patients were systematically searched.
Parkinsonian gait ameliorated with a moving handrail, not with a banister.
Arch Phys Med Rehabil
April 2015
Objective: To determine whether haptic (touch and proprioception) cues from touching a moving handrail while walking can ameliorate the gait symptoms of Parkinson disease (PD), such as slowness and small stride length.
Design: Nonrandomized, controlled before-after trial.
Setting: Physical therapy clinic.